UConn Health trial
A phase1 trial is underway to see if investigational medication messenger ribonucleic acid 3745 is tolerable and safe, with the hope that the same technology that has been successful in Covid vaccines can instruct the body to make the protein missing in GSD1a.
More information can be found on the UConn website:
UConn Health – Breaking Barriers